AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
This article was originally published in The Pink Sheet Daily
Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.
You may also be interested in...
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience
Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.